Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.

Falchook, G S; Moulder, S L; Wheler, J J; Jiang, Y; Bastida, C C; Kurzrock, R

Falchook, G S; Moulder, S L; Wheler, J J; Jiang, Y; Bastida, C C; Kurzrock, R.

Affiliation

Falchook GS; Department of Investigational Cancer Therapeutics (Phase I Program).

Ann Oncol ; 24(12): 3004-11, 2013 Dec.

Article in En | MEDLINE | ID: mdl-24158411

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Brain Neoplasms/drug therapy; Breast Neoplasms/drug therapy; Carcinoma, Ductal, Breast/drug therapy; Receptor, ErbB-2/metabolism; Receptors, Vascular Endothelial Growth Factor/metabolism; Adult; Aged; Antibodies, Monoclonal, Humanized/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/pharmacology; Bevacizumab; Brain Neoplasms/metabolism; Brain Neoplasms/secondary; Breast Neoplasms/metabolism; Breast Neoplasms/pathology; Carcinoma, Ductal, Breast/metabolism; Carcinoma, Ductal, Breast/secondary; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines/administration & dosage; Receptor, ErbB-2/antagonists & inhibitors; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors; Trastuzumab; Treatment Outcome

Key words

bevacizumab; breast cancer; her2; lapatinib; trastuzumab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Ductal, Breast / Receptor, ErbB-2 / Receptors, Vascular Endothelial Growth Factor Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2013 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google